Listed by the USPTO as PURDY, KYLE A
Tech Center 1600 • Art Units: 1611 1637
This examiner grants 41% of resolved cases
PURDY, KYLE A works in Tech Center 1600 and Art Unit 1611, with 1001 resolved cases. The allowance rate is 41.0%, the interview lift is 35.7%, and the median time to allowance is 1520 days. The combination suggests that interviews may be a particularly important prosecution tool in this docket, even though the overall allowance rate is lower.
Textile-Based Delivery Inc., Conopco, Inc. d/b/a Unilever, and University of Florida Research Foundation Inc. are the leading companies. NEO IP, Abel Schillinger, LLP, and ALSTON & BIRD LLP are the leading firms. Practitioners may want to integrate interview planning early when managing cases in this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630843 | SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18821462 | POLYANION COATED LIPID NANOPARTICLES AND METHODS OF USE THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18667002 | SKIN CARE SERUM COMPOSITION WITH NATURAL POLYMERS | Final Rejection | The Procter & Gamble Company |
| 18703637 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Ohio State Innovation Foundation |
| 18700612 | PLANT DISEASE RESISTANCE INDUCING METHOD, PLANT DISEASE RESISTANCE INDUCING DEVICE, AND PLANT DISEASE RESISTANCE INDUCING AGENT | Final Rejection | TOHOKU UNIVERSITY |
| 17056797 | MICROBIAL MICROCAPSULE COMPOSITIONS, METHODS AND RELATED METHODS | Non-Final OA | NEWLEAF SYMBIOTICS, INC. |
| 18706889 | METHODS AND SYSTEMS FOR POINT-OF-CARE SYNTHESIS AND ADMINISTRATION OF PARTICLE-BASED THERAPEUTICS | Final Rejection | Verily Life Sciences LLC |
| 18256655 | EXTRACT OF AT LEAST ONE PLANT OF THE CROCUS SATIVUS SPECIES COMPRISING A HIGH CONTENT OF CROCINS AND A LOW CONTENT OF SAFRANAL, AND COSMETIC USE THEREOF AS ANTIOXIDANT | Final Rejection | L'OREAL |
| 18396092 | Multicolored Oral Care Compositions and Methods for the Same | Final Rejection | Colgate-Palmolive Company |
| 17989516 | OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONS | Non-Final OA | S. C. Johnson & Son, Inc. |
| 17422859 | ANTIBACTERIAL COMPOSITION | Non-Final OA | LG CHEM, LTD. |
| 19001161 | COSMETIC COMPOSITIONS COMPRISING A CYCLODEXTRIN HAVING A PARTICLE SIZE DISTRIBUTION | Non-Final OA | ROQUETTE FRERES |
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18178041 | COMPOSITION FOR IMPROVING THE APPEARANCE OF AGEING SKIN | Non-Final OA | MERZ PHARMA GMBH & CO. KGAA |
| 18633246 | LIGHT-ACTIVATED CHLORINE DIOXIDE-RELEASING POWDER | Final Rejection | PHIEX TECHNOLOGIES, INC. |
| 18227116 | DELIVERY SYSTEMS | Non-Final OA | Textile-Based Delivery, Inc. |
| 18215445 | DELIVERY SYSTEMS | Non-Final OA | Textile-Based Delivery, Inc. |
| 18137744 | DELIVERY SYSTEMS | Final Rejection | Textile-Based Delivery, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.0% of resolved applications examined by Kyle A Purdy were allowed (1,001 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +35.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kyle A Purdy took 1,520 days on average from filing to allowance.
Kyle A Purdy examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
